Because DLL3 is overexpressed in certain tumor cells, the current principle of therapeutic targeting of DLL3 is mainly to kill cancer cells by targeting DLL3 with antibody-coupled cytotoxic drugs or by specifically targeting cancer cells with high DLL3 expression through CD3-activated T cells (Owen et al., 2019). This evidence concerns the gene DLL3 and neoplasm.